Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
News|Articles|May 30, 2025
Pharmacy Practice in Focus: Oncology
- July 2025
- Volume 7
- Issue 5
Patient Reported Outcomes Show Improved Symptoms With Zongertinib for HER2-Mutated Non-Small Cell Lung Cancer
Zongertinib shows significant benefits in managing symptoms and improving quality of life for patients with HER2-mutated non-small cell lung cancer.
Advertisement
Advertisement
Zongertinib (Boehringer Ingelheim) yielded clinically meaningful improvements in disease-related symptoms, physical functioning, and symptomatic adverse events (AEs) in patients with human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC). The patient-reported outcomes (PROs) from the Beamion LUNG-1 trial (NCT04886804) will be presented at the 2025 ASCO Annual Meeting in Chicago, Illinois.1
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
Advertisement
Advertisement